image
Healthcare - Medical - Care Facilities - NASDAQ - GB
$ 4.63
-3.54 %
$ 430 M
Market Cap
-2.33
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CMPS stock under the worst case scenario is HIDDEN Compared to the current market price of 4.63 USD, COMPASS Pathways plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CMPS stock under the base case scenario is HIDDEN Compared to the current market price of 4.63 USD, COMPASS Pathways plc is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CMPS stock under the best case scenario is HIDDEN Compared to the current market price of 4.63 USD, COMPASS Pathways plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CMPS

image
$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-178 M OPERATING INCOME
-30.15%
-155 M NET INCOME
-30.94%
-119 M OPERATING CASH FLOW
-22.40%
0 INVESTING CASH FLOW
100.00%
63.8 M FINANCING CASH FLOW
-63.28%
0 REVENUE
0.00%
-49.6 M OPERATING INCOME
-2.48%
-17.9 M NET INCOME
58.77%
-45.7 M OPERATING CASH FLOW
-9.34%
0 INVESTING CASH FLOW
0.00%
140 M FINANCING CASH FLOW
90454.19%
Balance Sheet COMPASS Pathways plc
image
Current Assets 201 M
Cash & Short-Term Investments 165 M
Receivables 21.8 M
Other Current Assets 14.4 M
Non-Current Assets 12.4 M
Long-Term Investments 469 K
PP&E 2.2 M
Other Non-Current Assets 9.71 M
77.26 %10.21 %6.73 %4.54 %Total Assets$213.7m
Current Liabilities 34 M
Accounts Payable 12.3 M
Short-Term Debt 7.24 M
Other Current Liabilities 14.5 M
Non-Current Liabilities 25 M
Long-Term Debt 25 M
Other Non-Current Liabilities 1
20.83 %12.27 %24.58 %42.32 %Total Liabilities$59.0m
EFFICIENCY
Earnings Waterfall COMPASS Pathways plc
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 178 M
Operating Income -178 M
Other Expenses -23.1 M
Net Income -155 M
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)000(178m)(178m)23m(155m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-100.28% ROE
-100.28%
-72.60% ROA
-72.60%
-94.36% ROIC
-94.36%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis COMPASS Pathways plc
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20192019202020202021202120222022202320232024202420252025
Net Income -155 M
Depreciation & Amortization 233 K
Capital Expenditures 0
Stock-Based Compensation 19.5 M
Change in Working Capital 11.7 M
Others 9.6 M
Free Cash Flow -119 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets COMPASS Pathways plc
image
Wall Street analysts predict an average 1-year price target for CMPS of $23 , with forecasts ranging from a low of $23 to a high of $23 .
CMPS Lowest Price Target Wall Street Target
23 USD 396.76%
CMPS Average Price Target Wall Street Target
23 USD 396.76%
CMPS Highest Price Target Wall Street Target
23 USD 396.76%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership COMPASS Pathways plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
16.1 M USD 3
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Meta to roll out AI-powered ad creation by late 2025, says WSJ Meta Platforms Inc (NASDAQ:META, ETR:FB2A, SWX:FB) is planning to let brands fully create and target ads using its artificial intelligence tools by the end of 2025, according to a report in the Wall Street Journal. Citing people familiar with the plans, the report says advertisers will be able to provide a product image and budget, and Meta’s AI will handle everything from generating the content, including text, images and video, to targeting users across Facebook and Instagram. Meta already uses AI to customise ads and suggest variations, but the new tools would go further by offering real-time personalisation based on factors like location. The company is also working on automating budget recommendations. With 3.43 billion global users across its apps, Meta sees advanced AI tools as a way to deliver ad results at scale. The move comes as rivals such as Snap, Pinterest and Reddit ramp up their own AI offerings in an increasingly competitive digital ad market. atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO and co-founder Dr Srinivas Rao talked with Proactive about the company’s clinical development progress in 2025, highlighting multiple upcoming trial readouts. Proactive: Hello, you're watching Proactive. Joining me is atai Life Sciences CEO and co-founder Dr Srinivas Rao. Srinivas, very good to speak with you. You've had a very busy start to 2025. Let's start off with the positive topline data of part two of the Beckley Psytech’s Phase 2a trial of BPL-003. It looks pretty encouraging. Dr Srinivas Rao: Yeah. Well, thanks for having me on. Yeah, we're very excited by that. So this is a continuation of a Phase 2a that we reported the results on last year actually. That was a single administration of BPL-003 in folks who were not taking an SSRI at that time. This is the continuation with those patients that are currently on an SSRI. Once again, we saw very good safety and tolerability and very robust efficacy in this cohort. So certainly important data as we move forward into Phase 3 with this program. The next step here is we're waiting for the results from the large Phase 2b trial that's currently ongoing. And if those results are as encouraging as the ones you just mentioned, when would you be expecting to go ahead with the Phase 3 trial? I mean, we haven't officially guided on that. And of course, the reason for that is it's going to depend upon the results as well as discussions with the FDA. But generally speaking, we can anticipate something starting sometime next year — obviously, sort of middle of next year, perhaps a little later. So you mentioned data from the Phase 2b study, which is expected in the middle of the year. Srinivas, lots of key readouts are expected this year and going into 2026. Take us through some of the other important ones. Yeah, we've got quite a few coming up. So we have the BPL-003 Phase 2b that we were talking about now — that's mid-year. RL-007, the large Phase 2b in cognitive impairment in schizophrenia, also in the middle of this year. Sort of right on top of this one, we’ll see which one comes first. And then early next year, the VLS-01 Illumina study that's currently ongoing should be reading out as well. We just recently initiated a Phase 2a study of EMP-01 in social anxiety disorder. That too is expected to read out in the first quarter of next year. And you announced the dosing of the first patients in that EMP-01 trial. Srinivas, tell us more about the trial and what it’s targeted at? Yeah, I mean again, it's an exploratory study. We wanted to go after a different indication. There's really no one focused on social anxiety disorder currently with a psychedelic compound. It’s using EMP-01, which we had reported results on in January or so last year. From our Phase 1, we found some very interesting properties of that compound — specifically that it had these antiketogenic effects like MDMA, but it also had psychedelic effects as well. So, a really interesting profile — a blend of these two classes in many ways. We spent time looking for the appropriate indication for that and ultimately made the decision to move forward with social anxiety disorder. There is some limited data for MDMA in social anxiety disorder, particularly in the autism subset, where social anxiety disorder is quite prominent. We are looking at broader social anxiety disorder with this. The trial broadly is a six-week study, with two administrations of EMP-01 — on day one and then at week four — and then a readout at week six. We're using a regulatory endpoint there, the so-called Liebowitz Social Anxiety Scale (LSAS). Again, very excited to see how this drug performs in this really important patient population, one that has a huge unmet medical need — bigger than depression — and yet has very limited options, at least from the therapeutic options for the treatment. Srinivas, apart from all of those readouts, any other milestones that your investors should be looking out for as 2025 progresses? I think in terms of the things that people will be really focused on, those are the main ones. The readouts are obviously the key right now. Obviously, there are other readouts in the space that we're all looking at. Compass being an important one. We do remain a shareholder in Compass. They have an interim readout that is also middle of this year. First quarter of next year, I believe, is when the totality of the so-called 005 study will read out. So again, that's going to be a big one for the space, of course. Quotes have been lightly edited for clarity and style https://www.proactiveinvestors.com - 3 weeks ago
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 1 month ago
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the 2025 RBC Capital Markets Global Healthcare Conference at 10:30 am ET on May 20th, 2025. A live audio webcast of the presentation will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the web. businesswire.com - 1 month ago
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Steve Schultz - SVP, IR Kabir Nath - CEO Teri Loxam - CFO Guy Goodwin - Chief Medical Officer Steve Levin - Chief Patient Officer Conference Call Participants Paul Matteis - Stifel Charles Duncan - Cantor Fitzgerald Athena Chin - TD Cowen Sumant Kulkarni - Canaccord Genuity Patrick Trucchio - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by. seekingalpha.com - 1 month ago
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. “We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said Kabir. businesswire.com - 1 month ago
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into a strategic collaboration with HealthPort, a multi-site comprehensive community health organization. HealthPort employs an integrated model centered around social determinants of health and this collaboration will help inform the potential delivery of COMP360 synthesized psilocybin treatment in. businesswire.com - 2 months ago
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025 LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2025, and provide an update on recent developments, on May 8, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 8, 2025. A live webcast of the call will be available on the Compass Pat. businesswire.com - 2 months ago
Why Compass Pathways Stock Was a Double-Digit Winner This Week The field of psychedelic medicine is relatively new, and because of this, certain investors consider it to be loaded with potential. That's why even minor events in companies specializing in this can be greeted with notable share price pops. fool.com - 2 months ago
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that all participants have completed dosing in Part A of the COMP005 phase 3 trial for treatment resistant depression (TRD). Following pre-dosing activities, including washout from anti-depressant medications, if needed, participants received a single dose of either 25 mg of COMP360 or placebo. The Company is on t. businesswire.com - 2 months ago
This Is a Test From GlobeNewswire This is a test from GlobeNewswire. Readers are advised to disregard. globenewswire.com - 3 months ago
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the completion of recruitment in the COMP005 phase 3 trial for treatment resistant depression (TRD). The final participants are completing pre-dosing activities, including washout from anti-depressant medications, if necessary, and those eligible will receive a dose of either 25 mg of COMP360 or placebo. “We are p. businesswire.com - 3 months ago
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the publication of results from the COMP004 study, an observational 52-week follow-up from the Phase 2 COMP001 and COMP003 trials of COMP360 psilocybin treatment in patients with treatment-resistant depression (TRD). The COMP004 study's findings suggest that over a 52-week period, a single administration of 25 mg. businesswire.com - 3 months ago
8. Profile Summary

COMPASS Pathways plc CMPS

image
COUNTRY GB
INDUSTRY Medical - Care Facilities
MARKET CAP $ 430 M
Dividend Yield 0.00%
Description COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Contact 33 Broadwick Street, London, W1F 0DQ https://compasspathways.com
IPO Date Sept. 18, 2020
Employees 166
Officers Dr. Susan C. Stansfield Ph.D. Advisor Mr. Kabir Kumar Nath M.A., M.B.A. Chief Executive Officer & Director Dr. Greg Ryslik Ph.D. Chief Technology Officer Ms. Lori Englebert M.B.A. Chief Commercial Officer Dr. Michael Gold M.D., M.Sc. Chief Research & Development Officer Mr. Lars Christian Wilde Senior Advisor Dr. Guy Goodwin Chief Medical Officer Ms. Teri Loxam M.B.A. Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer Mr. Stephen D. Schultz Senior Vice President of Investor Relations Ms. Anne Benedict Chief People Officer